Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention

Brandi, Giovanni; Lorenzo, Stefania De; Palloni, Andrea; Biasco, Guido; Tovoli, Francesco

doi:10.1002/hep.28999

Search citation statements

Order By: Relevance

Paper Sections

Select...

An Experiments About Aspirin On the Risk Of Hepatocellular C...1

Epidemiological Evidence For the Prevention Of Cancer By Asp1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the results, the use of aspirin can reduce the risk of HCC in a dose-dependent manner. In general, the risk of HCC will decrease with the increase of dose [6].…”

Section: An Experiments About Aspirin On the Risk Of Hepatocellular C...mentioning

confidence: 99%

Drug Reposition: The Analysis of the Possibility of Using Aspirin for the Prevention of Cancers

Jin

2023

IJCEMR

View full text Add to dashboard Cite

show abstract

“…According to the results, the use of aspirin can reduce the risk of HCC in a dose-dependent manner. In general, the risk of HCC will decrease with the increase of dose [6].…”

Section: An Experiments About Aspirin On the Risk Of Hepatocellular C...mentioning

confidence: 99%

Drug Reposition: The Analysis of the Possibility of Using Aspirin for the Prevention of Cancers

Jin

2023

IJCEMR

View full text Add to dashboard Cite

show abstract

“…The prognosis for patients with cholangiocarcinoma is very poor . Individuals with primary sclerosing cholangitis or exposure to asbestos are at high risk of cholangiocarcinoma . After a radical surgical resection of cholangiocarcinoma, the recurrence rate is as high as 60% .…”

Section: Epidemiological Evidence For the Prevention Of Cancer By Aspmentioning

confidence: 99%

Complex roles of the old drug aspirin in cancer chemoprevention and therapy

Hua

Zhang

Kong

et al. 2018

Medicinal Research Reviews

View full text Add to dashboard Cite

The nonsteroidal anti-inflammatory agent aspirin is widely used for preventing and treating cardiovascular and cerebrovascular diseases. In addition, epidemiologic evidences reveal that aspirin may prevent a variety of human cancers, while data on the association between aspirin and some kinds of cancer are conflicting. Preclinical studies and clinical trials also reveal the therapeutic effect of aspirin on cancer. Although cyclooxygenase is a well-known target of aspirin, recent studies uncover other targets of aspirin and its metabolites, such as AMP-activated protein kinase, cyclin-dependent kinase, heparanase, and histone. Accumulating evidence demonstrate that aspirin may act in different cell types, such as epithelial cell, tumor cell, endothelial cell, platelet, and immune cell. Therefore, aspirin acts on diverse hallmarks of cancer, such as sustained tumor growth, metastasis, angiogenesis, inflammation, and immune evasion. In this review, we focus on recent progress in the use of aspirin for cancer chemoprevention and therapy, and integratively analyze the mechanisms underlying the anticancer effects of aspirin and its metabolites. We also discuss mechanisms of aspirin resistance and describe some derivatives of aspirin, which aim to overcome the adverse effects of aspirin.

show abstract

Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention

Cited by 2 publications

References 5 publications

Drug Reposition: The Analysis of the Possibility of Using Aspirin for the Prevention of Cancers

Drug Reposition: The Analysis of the Possibility of Using Aspirin for the Prevention of Cancers

Complex roles of the old drug aspirin in cancer chemoprevention and therapy

Contact Info

Product

Resources

About